Promising cocktail for tough cancer? early trial combines immunotherapy, targeted pill, and radiation
NCT ID NCT07455019
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of the immunotherapy drug bemosubaiabimab, the targeted pill anlotinib, plus radiation and chemotherapy can help people with oligometastatic esophageal cancer—cancer that has spread to a few spots. About 28 participants will receive up to 6 cycles of the combo, then continue on the two drugs alone. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bemosubaiabimab (a drug given by IV) plus anlotinib hydrochloride (a pill taken by mouth), along with radiation and chemotherapy
What this could lead to
If it works, this could point toward a new combination treatment that shrinks tumors and delays progression in people with limited-spread esophageal cancer.
What could go wrong
This is a small, early-phase trial with only 28 people and no comparison group, so results may not apply broadly. The combination also carries risks from chemotherapy, radiation, and immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-••••